{"id":24833,"date":"2026-02-02T01:09:08","date_gmt":"2026-02-02T01:09:08","guid":{"rendered":"https:\/\/indiabulletinusa.com\/wordpress\/2026\/02\/02\/fund-slashes-12-5-million-stake-in-healthcare-tech-after-60-drop\/"},"modified":"2026-02-02T01:09:08","modified_gmt":"2026-02-02T01:09:08","slug":"fund-slashes-12-5-million-stake-in-healthcare-tech-after-60-drop","status":"publish","type":"post","link":"https:\/\/indiabulletinusa.com\/wordpress\/2026\/02\/02\/fund-slashes-12-5-million-stake-in-healthcare-tech-after-60-drop\/","title":{"rendered":"Fund Slashes $12.5 Million Stake in Healthcare Tech After 60% Drop"},"content":{"rendered":"


\n<\/p>\n

Chicago Capital Reduces Stake in PROCEPT BioRobotics<\/strong><\/p>\n

On January 26, Chicago Capital announced through a filing with the SEC that it has decreased its investment in PROCEPT BioRobotics (NASDAQ: PRCT) by selling 377,850 shares during the fourth quarter. This sale is estimated to be worth about $12.53 million, based on average market prices for the quarter.<\/p>\n

Following this transaction, Chicago Capital’s remaining investment in PROCEPT is now valued at $37.47 million. The overall value of this position decreased by $18.52 million, impacted by both share sales and fluctuations in stock prices.<\/p>\n

In terms of percentages, Chicago Capital’s investment in PROCEPT now represents 0.93% of its total assets, down from 1.38% in the previous quarter.<\/p>\n

Top Holdings Post-Filing:<\/strong><\/p>\n

    \n
  1. Alphabet (GOOGL):<\/strong> $248.84 million (6.15% of total assets)<\/li>\n
  2. Meta Platforms (META):<\/strong> $189.10 million (4.67% of total assets)<\/li>\n
  3. Amazon (AMZN):<\/strong> $168.92 million (4.17% of total assets)<\/li>\n
  4. Nvidia (NVDA):<\/strong> $148.39 million (3.66% of total assets)<\/li>\n
  5. Visa (V):<\/strong> $141.11 million (3.49% of total assets)<\/li>\n<\/ol>\n

    As of January 26, the shares of PROCEPT BioRobotics were priced at $29.61, reflecting a significant decline of 60.4% over the past year. In contrast, the S&P 500 index rose approximately 14% in the same timeframe.<\/p>\n

    Company Overview<\/strong>
    \nPROCEPT BioRobotics specializes in robotic systems for minimally invasive urologic surgery, focusing on treating benign prostatic hyperplasia (BPH). The company generates revenue by selling robotic systems, single-use consumables, and service contracts. It primarily caters to hospitals and urology centers serving male patients with urinary issues related to BPH.<\/p>\n

    Despite facing challenges, PROCEPT continues to grow. In its most recent quarter, it reported a revenue increase of 43% year-over-year, reaching $83.3 million, with a 65% gross margin. The company has set a revenue target between $410 million and $430 million for 2026, signaling potential growth of up to 32% from 2025 levels.<\/p>\n

    While the company is expanding, its stock performance has been lackluster. Over the last year, fears about operating losses and high spending have led to a drop in share prices. In its latest quarterly report, PROCEPT recorded an adjusted EBITDA loss of $7.4 million and is still investing heavily in its growth.<\/p>\n

    In a broader context, Chicago Capital’s strategy appears to reflect a focus on reducing exposure to more volatile investments while maintaining stronger positions in stable tech companies.<\/p>\n\n","protected":false},"excerpt":{"rendered":"

    Chicago Capital Reduces Stake in PROCEPT BioRobotics On January 26, Chicago Capital announced through a filing with the SEC that it has decreased its investment in PROCEPT BioRobotics (NASDAQ: PRCT) by selling 377,850 shares during the fourth quarter. This sale is estimated to be worth about $12.53 million, based on average market prices for the<\/p>\n","protected":false},"author":1,"featured_media":24834,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rank_math_lock_modified_date":false,"footnotes":""},"categories":[34],"tags":[32022,32028,32021,32024,32027,32023,32026,1046,32025],"class_list":["post-24833","post","type-post","status-publish","format-standard","has-post-thumbnail","category-technology","tag-aum","tag-benign-prostatic-hyperplasia","tag-chicago-capital","tag-installed-base","tag-january-26","tag-procept","tag-robotic-systems","tag-securities-and-exchange-commission","tag-stock-price-movement"],"_links":{"self":[{"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/posts\/24833","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/comments?post=24833"}],"version-history":[{"count":0,"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/posts\/24833\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/media\/24834"}],"wp:attachment":[{"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/media?parent=24833"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/categories?post=24833"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/tags?post=24833"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}